Literature DB >> 31403467

Human fecal metabolomic profiling could inform Clostridioides difficile infection diagnosis and treatment.

Casey M Theriot, Joshua R Fletcher.   

Abstract

Clostridioides difficile is a significant public health threat, and diagnosis of this infection is challenging due to a lack of sensitivity in current diagnostic testing. In this issue of the JCI, Robinson et al. use a logistic regression model based on the fecal metabolome that is able to distinguish between patients with non-C. difficile diarrhea and C. difficile infection, and to some degree, patients who are asymptomatically colonized with C. difficile. The authors construct a metabolic definition of human C. difficile infection, which could improve diagnostic accuracy and aid in the development of targeted therapeutics against this pathogen.

Entities:  

Mesh:

Year:  2019        PMID: 31403467      PMCID: PMC6715351          DOI: 10.1172/JCI130008

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

1.  Extension of the Stickland reaction to several bacterial species.

Authors:  B NISMAN; M RAYNAUD; G N COHEN
Journal:  Arch Biochem       Date:  1948-03

2.  Systems biology: Metabonomics.

Authors:  Jeremy K Nicholson; John C Lindon
Journal:  Nature       Date:  2008-10-23       Impact factor: 49.962

3.  Point-Counterpoint: What Is the Optimal Approach for Detection of Clostridium difficile Infection?

Authors:  Ferric C Fang; Christopher R Polage; Mark H Wilcox
Journal:  J Clin Microbiol       Date:  2017-01-11       Impact factor: 5.948

Review 4.  Interactions Between the Gastrointestinal Microbiome and Clostridium difficile.

Authors:  Casey M Theriot; Vincent B Young
Journal:  Annu Rev Microbiol       Date:  2015       Impact factor: 15.500

Review 5.  Integration of metabolism and virulence in Clostridium difficile.

Authors:  Laurent Bouillaut; Thomas Dubois; Abraham L Sonenshein; Bruno Dupuy
Journal:  Res Microbiol       Date:  2014-10-15       Impact factor: 3.992

6.  Burden of Clostridium difficile infection in the United States.

Authors:  Fernanda C Lessa; Yi Mu; Wendy M Bamberg; Zintars G Beldavs; Ghinwa K Dumyati; John R Dunn; Monica M Farley; Stacy M Holzbauer; James I Meek; Erin C Phipps; Lucy E Wilson; Lisa G Winston; Jessica A Cohen; Brandi M Limbago; Scott K Fridkin; Dale N Gerding; L Clifford McDonald
Journal:  N Engl J Med       Date:  2015-02-26       Impact factor: 91.245

7.  Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection.

Authors:  Alexa R Weingarden; Chi Chen; Aleh Bobr; Dan Yao; Yuwei Lu; Valerie M Nelson; Michael J Sadowsky; Alexander Khoruts
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-11-27       Impact factor: 4.052

Review 8.  Bile Acid sulfation: a pathway of bile acid elimination and detoxification.

Authors:  Yazen Alnouti
Journal:  Toxicol Sci       Date:  2009-01-08       Impact factor: 4.849

9.  Bile salts and glycine as cogerminants for Clostridium difficile spores.

Authors:  Joseph A Sorg; Abraham L Sonenshein
Journal:  J Bacteriol       Date:  2008-02-01       Impact factor: 3.490

10.  Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection.

Authors:  Casey M Theriot; Mark J Koenigsknecht; Paul E Carlson; Gabrielle E Hatton; Adam M Nelson; Bo Li; Gary B Huffnagle; Jun Z Li; Vincent B Young
Journal:  Nat Commun       Date:  2014       Impact factor: 14.919

View more
  2 in total

1.  A Light-Weight Practical Framework for Feces Detection and Trait Recognition.

Authors:  Lu Leng; Ziyuan Yang; Cheonshik Kim; Yue Zhang
Journal:  Sensors (Basel)       Date:  2020-05-06       Impact factor: 3.576

2.  Decreased secondary faecal bile acids in children with ulcerative colitis and Clostridioides difficile infection.

Authors:  Sarah Rotondo-Trivette; Beibei Wang; Christopher Gayer; Riddhi Parsana; Yihui Luan; Fengzhu Sun; Sonia Michail
Journal:  Aliment Pharmacol Ther       Date:  2021-07-04       Impact factor: 9.524

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.